211 related articles for article (PubMed ID: 24513177)
21. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells.
Sirchia SM; Ferguson AT; Sironi E; Subramanyan S; Orlandi R; Sukumar S; Sacchi N
Oncogene; 2000 Mar; 19(12):1556-63. PubMed ID: 10734315
[TBL] [Abstract][Full Text] [Related]
22. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
23. The TCF4/β-catenin pathway and chromatin structure cooperate to regulate D-glucuronyl C5-epimerase expression in breast cancer.
Mostovich LA; Prudnikova TY; Kondratov AG; Gubanova NV; Kharchenko OA; Kutsenko OS; Vavilov PV; Haraldson K; Kashuba VI; Ernberg I; Zabarovsky ER; Grigorieva EV
Epigenetics; 2012 Aug; 7(8):930-9. PubMed ID: 22805760
[TBL] [Abstract][Full Text] [Related]
24. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
[TBL] [Abstract][Full Text] [Related]
25. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation.
Wu Y; Alvarez M; Slamon DJ; Koeffler P; Vadgama JV
BMC Cancer; 2010 Feb; 10():32. PubMed ID: 20132554
[TBL] [Abstract][Full Text] [Related]
26. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise A; Momparler RL
Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
[TBL] [Abstract][Full Text] [Related]
27. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
[TBL] [Abstract][Full Text] [Related]
28. Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.
Hostetter CL; Licata LA; Keen JC
Cancer Lett; 2009 Mar; 275(2):178-84. PubMed ID: 19013015
[TBL] [Abstract][Full Text] [Related]
29. COUP-TFII is a modulator of cell-type-specific genetic programs based on genomic localization maps.
Erdős E; Bálint BL
J Biotechnol; 2019 Aug; 301():11-17. PubMed ID: 31158411
[TBL] [Abstract][Full Text] [Related]
30. Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines.
Moré E; Fellner T; Doppelmayr H; Hauser-Kronberger C; Dandachi N; Obrist P; Sandhofer F; Paulweber B
J Endocrinol; 2003 Jan; 176(1):83-94. PubMed ID: 12525252
[TBL] [Abstract][Full Text] [Related]
31. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells.
Yap OW; Bhat G; Liu L; Tollefsbol TO
Anticancer Res; 2009 Jan; 29(1):139-44. PubMed ID: 19331143
[TBL] [Abstract][Full Text] [Related]
33. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac.
Liu Y; Jin X; Li Y; Ruan Y; Lu Y; Yang M; Lin D; Song P; Guo Y; Zhao S; Dong B; Xie Y; Dang Q; Quan C
J Exp Clin Cancer Res; 2016 Jul; 35(1):120. PubMed ID: 27461117
[TBL] [Abstract][Full Text] [Related]
35. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
37. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
38. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
[TBL] [Abstract][Full Text] [Related]
39. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
Rivenbark AG; Jones WD; Coleman WB
Lab Invest; 2006 Dec; 86(12):1233-42. PubMed ID: 17043665
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
